Repeat CRP measurements and incident myocardial infarction

Read full text
Authors: Daniel Weiner, Buu Truong, Satoshi Koyama, Kaavya Paruchuri, Whitney Hornsby, Michael Honigberg, Pradeep Natarajan
Cited by: 2
References: 24

Abstract

Background Inflammation is a causal risk factor for cardiovascular disease. While individuals with elevated levels of inflammation may benefit from targeted therapy, population-level stability of inflammation over time is poorly defined, as is the relationship between repeated measures of inflammatory markers and incident myocardial infarction. C-reactive protein (CRP) is among the best-established inflammatory markers. Objectives To examine (i) the stability of CRP over repeat measurements and (ii) the association between patterns of repeated CRP and rates of first-time myocardial infarction. Methods The relationship between baseline and repeat assessment of CRP was analyzed in 14,960 individuals from the UK Biobank without a diagnosed underlying inflammatory condition. The association between baseline and repeat CRP and first-time myocardial infarction was estimated using a Cox proportional hazards model. Results Among the analyzed cohort, median (IQR) age was 58 (52–63) years, 7,564 (51%) were female, and median (IQR) CRP was 1.1 (0.6–2.3) mg/L at baseline. Baseline and repeat CRP were correlated (Spearman rho 0.64) across a median (IQR) follow-up interval of 4.4 (3.7–4.9) years. Among the 10,566 (71%) individuals with non-elevated CRP ( 0.05). Conclusions Persistently elevated CRP was significantly associated with incident first-time myocardial infarction. This finding highlights the importance of repeated measurement of inflammatory markers for cardiovascular risk stratification.

Fields of Study & Subjects

Cardiovascular Function and Risk Factors Inflammatory Biomarkers in Disease Prognosis Hemodynamic Monitoring and Therapy

Publication details

Journal / source
American Journal of Preventive Cardiology
Publisher
Elsevier BV
Volume
27
Pages
101486–101486
Publication date
24 March 2026
Language
EN